ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. **NAME OF THE MEDICINAL PRODUCT**

KIMMTRAK 100 micrograms/0.5 mL concentrate for solution for infusion

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

One 0.5 mL vial contains 100 micrograms of tebentafusp, corresponding to a concentration before dilution of 200 mcg/mL.

Tebentafusp is a fusion protein, produced by recombinant DNA technology in *Escherichia coli* cells.

For the full list of excipients, see section 6.1.

3. **PHARMACEUTICAL FORM**

Concentrate for solution for infusion (sterile concentrate).

Clear, colourless to slightly yellowish solution in a single-dose vial.

4. **CLINICAL PARTICULARS**

4.1 **Therapeutic indications**

KIMMTRAK is indicated as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

4.2 **Posology and method of administration**

KIMMTRAK should be administered under the direction and supervision of a physician experienced in the use of anti-cancer agents and who is prepared to manage cytokine release syndrome in an environment where full resuscitation facilities are immediately available. Hospitalisation is recommended for at least the first three infusions of KIMMTRAK (see section 4.4).

Patients treated with KIMMTRAK must have HLA-A*02:01 genotype determined by any validated HLA genotyping assay.

**Posology**

The recommended dose of KIMMTRAK is 20 micrograms on Day 1, 30 micrograms on Day 8, 68 micrograms on Day 15, and 68 micrograms once every week thereafter (see section 6.6). Treatment with KIMMTRAK should be continued while patient is deriving clinical benefit and in the absence of unacceptable toxicities (see section 5.1).

**Premedication**

To minimize the risk of hypotension associated with cytokine release syndrome (CRS), intravenous fluids should be administered prior to starting KIMMTRAK infusion based on clinical evaluation and the volume status of the patient.
For patients with preexisting adrenal insufficiency on maintenance systemic corticosteroids, adjusting the corticosteroid dose should be considered to manage the risk of hypotension.

Dose adjustments

No dose reductions of KIMMTRAK are recommended. KIMMTRAK should be withheld or discontinued to manage adverse reactions as described in Table 1 and Table 2.

If CRS is suspected, the symptoms should be identified and promptly managed according to recommendations in Table 1. See Table 2 for management guidelines for acute skin reactions.

Table 1: CRS grading and management guidance

<table>
<thead>
<tr>
<th>CRS grade*</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Grade 1</strong></td>
<td></td>
</tr>
<tr>
<td>Temperature ≥ 38 °C</td>
<td></td>
</tr>
<tr>
<td>No hypotension or hypoxia</td>
<td></td>
</tr>
<tr>
<td>• Continue treatment and provide symptomatic support. Monitor for escalation in CRS severity.</td>
<td></td>
</tr>
<tr>
<td><strong>Grade 2</strong></td>
<td></td>
</tr>
<tr>
<td>Temperature ≥ 38 °C</td>
<td></td>
</tr>
<tr>
<td>Hypotension that responds to fluids and does not require vasopressors</td>
<td></td>
</tr>
<tr>
<td>Oxygen requirement includes low flow nasal cannula (delivery of oxygen ≤ 6 L/min) or blow-by</td>
<td></td>
</tr>
<tr>
<td>• Continue treatment and administer bolus intravenous fluids and oxygen by low flow nasal cannula or blow-by oxygen as needed.</td>
<td></td>
</tr>
<tr>
<td>• If hypotension and hypoxia do not improve within 3 hours or CRS worsens administer high-dose intravenous corticosteroid (e.g. 2 mg/kg/day methylprednisolone or equivalent).</td>
<td></td>
</tr>
<tr>
<td>• For Grade 2 CRS that is persistent (lasting 2-3 hours) or recurrent (occurrence of ≥ Grade 2 CRS with more than one dose), administer corticosteroid premedication (e.g. dexamethasone 4 mg or equivalent) at least 30 minutes prior to next dose</td>
<td></td>
</tr>
<tr>
<td><strong>Grade 3</strong></td>
<td></td>
</tr>
<tr>
<td>Temperature ≥ 38 °C</td>
<td></td>
</tr>
<tr>
<td>Require a vasopressor with or without vasopressin</td>
<td></td>
</tr>
<tr>
<td>Require high flow nasal cannula (delivery of oxygen &gt; 6 L/min), face mask or non-rebreather mask or Venturi mask</td>
<td></td>
</tr>
<tr>
<td>• Withhold KIMMTRAK until CRS and sequelae have resolved</td>
<td></td>
</tr>
<tr>
<td>• Administer high-dose intravenous corticosteroid (e.g. 2 mg/kg/day methylprednisolone or equivalent).</td>
<td></td>
</tr>
<tr>
<td>• Administer tocilizumab as needed</td>
<td></td>
</tr>
<tr>
<td>- Patient weight ≤ 30 kg: 12 mg/kg intravenously over 1 hour</td>
<td></td>
</tr>
<tr>
<td>- Patient weight ≥ 30 kg: 8 mg/kg intravenously over 1 hour (maximum dose 800 mg)</td>
<td></td>
</tr>
<tr>
<td>• Resume KIMMTRAK at same dose level (i.e., do not escalate if Grade 3 CRS occurred during initial dose escalation; resume escalation once dosage is tolerated)</td>
<td></td>
</tr>
</tbody>
</table>
For Grade 3 CRS, administer corticosteroid premedication (e.g. dexamethasone 4 mg or equivalent) at least 30 minutes prior to next dose

| Grade 4 | | **Grade 4**  
|---------|---|---
| Temperature ≥ 38 °C | **Permanently discontinue KIMMTRAK**  
| Require multiple vasopressors (excluding vasopressin) | **Administer intravenous corticosteroid (e.g., 2 mg/kg/day methylprednisolone or equivalent)**  
| Requiring positive pressure (e.g. CPAP, BiPAP, intubation and mechanical ventilation). | |

*Based on American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading of CRS criteria (Lee et. al 2019).*
<table>
<thead>
<tr>
<th>Adverse reactions (see section 4.4)</th>
<th>Severity(^a)</th>
<th>Management</th>
</tr>
</thead>
</table>
| Acute skin reactions              | Grade 2        | • Withhold KIMMTRAK until Grade \(\leq 1\) or baseline.  
                                     |                | • Administer antipruritic regimen (e.g., non-sedating long-acting antihistamine)  
                                     |                | • Administer topical corticosteroid treatment for symptomatic rash that does not respond to anti-pruritic regimen.  
                                     |                | • For persistent symptoms, administer systemic steroids  
                                     |                | • Resume KIMMTRAK escalation if the current dose is less than 68 mcg, or resume at same dose level if dose escalation has completed |
|                                   | Grade 3        | • Withhold KIMMTRAK until Grade \(\leq 1\) or baseline.  
                                     |                | • Administer topical corticosteroid and oral corticosteroids  
                                     |                | • For persistent reactions not responding to oral steroids, consider intravenous corticosteroid (e.g., 2 mg/kg/day methylprednisolone or equivalent)  
                                     |                | • Resume KIMMTRAK at same dose level (i.e., do not escalate if Grade 3 skin reactions occurred during initial dose escalation; resume escalation once dosage is tolerated) |
|                                   | Grade 4        | • Permanently discontinue KIMMTRAK  
                                     |                | • Administer intravenous corticosteroid (e.g., 2 mg/kg/day methylprednisolone or equivalent) |

\(^a\) Based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (NCI CTCAEv4.03).

**Special populations**

*Paediatric population*
The safety and efficacy of KIMMTRAK in children under the age of 18 years have not been established. No data are available.

**Elderly**

No dose adjustment is required for elderly patients (≥ 65 years of age).

**Renal impairment**

Based on safety and efficacy analyses, dose adjustment is not necessary in patients with mild to moderate renal dysfunction. No dose recommendations can be made for patients with severe renal impairment because of the lack of pharmacokinetic data; therefore, dosing in patients with severe renal impairment should be done with caution and careful monitoring (see section 5.2).

**Patients with history of cardiac disease**

KIMMTRAK has not been studied in patients with history of significant cardiac disease. Patients with cardiac disease, QT prolongation and risk factors for cardiac failure should be monitored carefully (see section 4.4).

**Method of administration**

KIMMTRAK is for intravenous use. The recommended infusion period is 15 to 20 minutes.

KIMMTRAK requires dilution with sodium chloride 9 mg/mL (0.9 %) solution for injection containing human albumin for intravenous infusion. Each vial of KIMMTRAK is intended for use as single-dose only. Do not shake the KIMMTRAK vial.

For instructions on dilution and administration of the medicinal product, see section 6.6.

**First three treatment doses**

First three doses of KIMMTRAK should be administered in a hospital setting with overnight monitoring for signs and symptoms of CRS for at least 16 hours. Vital signs should be monitored pre dose and at a minimum of every 4 hours until resolution of symptoms. If clinically indicated, more frequent monitoring or prolongation of hospitalization should be performed.

If patients experience Grade 3 or 4 hypotension during any of the first three KIMMTRAK infusions, patients should be monitored every hour for at least 4 hours in an outpatient setting for the next three infusions.

**Subsequent treatment doses**

After 68 mcg dose level is tolerated (i.e., absence of Grade ≥ 2 hypotension requiring medical intervention), subsequent doses can be administered in appropriate outpatient ambulatory care setting. Patients should be observed for a minimum of 60 minutes following each infusion. For patients who have received outpatient treatment with KIMMTRAK for at least 3 months and have not experienced any interruptions greater than 2 weeks, outpatient monitoring following infusion may be decreased to a minimum of 30 minutes for subsequent doses.

**4.3 Contraindications**

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

**4.4 Special warnings and precautions for use**

**Traceability**
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

**Cytokine release syndrome (CRS)**

Most patients experienced CRS following tebentafusp infusions. Diagnosis of CRS was most frequently based on pyrexia followed by hypotension and infrequently hypoxia. Other commonly observed symptoms with CRS included chills, nausea, vomiting, fatigue, and headache.

In the majority of cases, CRS started on the day of infusion with median time to resolution of 2 days. Pyrexia was noted in nearly all cases of CRS, and in these patients, an increase in body temperature generally occurred within the first 8 hours after tebentafusp infusion. CRS rarely (1.2 %) led to treatment discontinuation.

Patients should be monitored for signs or symptoms of CRS for at least 16 hours following first three infusions of tebentafusp in a hospital setting with immediate access to medicinal products and resuscitative equipment to manage CRS. If CRS is observed, prompt treatment with supportive care including antipyretics, intravenous fluids, tocilizumab, or corticosteroids should be initiated to avoid escalation to severe or life-threatening events and monitoring should be continued until resolution.

At subsequent doses, patients should be closely monitored after treatment for early identification of signs and symptoms of CRS (see section 4.2, Method of administration). Patients with co-morbidities, including cardiovascular disorders, may be at increased risk for sequela associated with CRS.

Treatment with tebentafusp has not been studied in patients with clinically significant cardiac disease (see section 5.1). Depending on persistence and severity of CRS tebentafusp treatment should be withheld or discontinued (see section 4.2, Table 1).

**Acute skin reactions**

Acute skin reactions have been reported with tebentafusp infusion, which may be based on its mechanism of action and gp100 expression in normal melanocytes in the skin. Acute skin reactions mainly included rash, pruritus, erythema and cutaneous oedema (see section 4.8).

Acute skin reactions typically occurred following each of the first three tebentafusp infusions and decreased in severity and frequency over time. Majority of symptoms resolved without any systemic corticosteroid or any long term sequela.

Acute skin reactions can be managed with antihistamine and topical corticosteroids. For persistent or severe symptoms, systemic steroids should be considered. Management of signs and symptoms of skin reactions may require temporary delays of subsequent tebentafusp treatments (see section 4.2, Table 2).

**Cardiac disease**

Cardiac events such as sinus tachycardia and arrhythmia have been observed in patients who have received tebentafusp treatment (see section 4.8). Patients with pre-existing cardiovascular disorders may be at increased risk for sequela associated with CRS and should be monitored carefully. Any patient with signs or symptoms consistent with cardiac events should be evaluated and promptly treated. In addition, appropriate treatment should be administered for any underlying CRS as a precipitating factor.

Cases of QT interval prolongation were reported following tebentafusp treatment (see section 4.8). Tebentafusp treatment should be administered with caution in patients with history of or predisposition to QT interval prolongation and in patients who are taking medicinal products that are known to prolong QT interval.
An electrocardiogram (ECG) should be performed in all patients before and after tebentafusp treatment during the first 3 weeks of treatment and subsequently as clinically indicated. If QTcF exceeds 500 msec or increases by ≥ 60 msec from baseline value tebentafusp treatment should be withheld and patients should be treated for any underlying precipitating factors including electrolyte abnormalities. Tebentafusp treatment should be resumed once QTcF interval improves to <500 msec or is < 60 msec from baseline value. Depending on persistence and severity of the cardiac event and any associated CRS tebentafusp treatment should be withheld or discontinued (see section 4.2, Table 1).

Contraception

Women of childbearing potential have to use effective contraception during and for at least 1 week after last dose of tebentafusp treatment (see section 4.6)

Excipients

This medicinal product contains less than 1 mmol sodium (23 mg) per mL, that is to say essentially ‘sodium-free’

4.5 Interaction with other medicinal products and other forms of interaction

No formal drug interaction studies have been performed with tebentafusp.

Initiation of tebentafusp treatment causes transient release of cytokines that may suppress CYP450 enzymes. The highest drug-drug interaction risk is during the first 24 hours of the first three doses of tebentafusp in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index. These patients should be monitored for toxicity (e.g., warfarin) or drug concentrations (e.g., cyclosporine). The dose of the concomitant medicines should be adjusted as needed.

4.6 Fertility, pregnancy and lactation

Women of childbearing potential/Contraception

Women of childbearing potential should use effective contraception during treatment with tebentafusp and for at least 1 week after last dose of tebentafusp.

Pregnancy

There are no data from the use of tebentafusp in pregnant women. Animal reproduction studies have not been conducted with tebentafusp (see section 5.3).

Tebentafusp is not recommended during pregnancy and in women of childbearing potential not using contraception. The pregnancy status in females of reproductive potential should be verified prior to initiating tebentafusp treatment.

Breast-feeding

There is insufficient information on the excretion of tebentafusp/metabolites in human milk. A risk to the newborns/infants cannot be excluded. Breast-feeding should be discontinued during treatment with tebentafusp.

Fertility

No fertility studies have been conducted with tebentafusp (see section 5.3). The effect of tebentafusp on male and female fertility is unknown.

4.7 Effects on ability to drive and use machines
Tebentafusp has no or negligible influence on the ability to drive and use machines.

4.8 Undesirable effects

Summary of safety profile

The most common adverse drug reactions in patients treated with KIMMTRAK were cytokine release syndrome (88 %), rash (85 %), pyrexia (79 %), pruritus (72 %), fatigue (66 %), nausea (56 %), chills (55 %), abdominal pain (49 %), oedema (49 %), hypo/hyperpigmentation (48 %), hypotension (43 %), dry skin (35 %), headache (32 %) and vomiting (34 %).

Adverse reactions led to permanent discontinuation in 4 % of patients receiving KIMMTRAK. The most common adverse reaction that led to discontinuation of KIMMTRAK was cytokine release syndrome.

Adverse reactions resulting in at least one dose interruption occurred in 26 % of KIMMTRAK-treated patients (dosed weekly) and resulted in a median of one skipped dose. Adverse reactions requiring dosage interruption in ≥ 2 % of patients included fatigue (3 %; Grade 1–3), pyrexia (2.7 %; Grade 1–3), alanine aminotransferase increase (2.4 %; Grade 1–4), aspartate aminotransferase increase (2.4 %; Grade 1–3) abdominal pain (2.1 %; Grade 1–3), and lipase increased (2.1 %; Grade 1–3).

Adverse reactions leading to at least one dose modification occurred in 4.2 % of patients in KIMMTRAK-treated group. Adverse reactions which required dose modification in ≥ 1 % of patients were cytokine release syndrome (1.9 %; Grade 1–3), and hypotension (1.1 %; Grade 2–4).

Tabulated list of adverse reactions

Table 3 summarizes adverse reactions that occurred in 378 metastatic uveal melanoma patients from two clinical studies (IMCgp100-102 and IMCgp100-202) that received the recommended dosing KIMMTRAK dosing regimen of 20 micrograms on Day 1, 30 micrograms on Day 8 and 68 micrograms on Day 15 and 68 micrograms weekly thereafter.

The adverse drug reaction frequency is listed by MedDRA System Organ Class (SOC) at the preferred term level. Frequencies of occurrence of adverse reactions are defined as: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.

<table>
<thead>
<tr>
<th>Table 3: Adverse reactions in patients treated with KIMMTRAK monotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Infections and infestations</strong></td>
</tr>
<tr>
<td>Common Nasopharyngitis</td>
</tr>
<tr>
<td><strong>Immune system disorders</strong></td>
</tr>
<tr>
<td>Very common Cytokine release syndrome¹</td>
</tr>
<tr>
<td><strong>Metabolism and nutrition disorders</strong></td>
</tr>
<tr>
<td>Very common Decreased appetite, hypomagnesaemia, hyponatraemia, hypocalcaemia, hypokalaemia</td>
</tr>
<tr>
<td>Uncommon Tumour lysis syndrome</td>
</tr>
<tr>
<td><strong>Psychiatric disorders</strong></td>
</tr>
<tr>
<td>Very Common Insomnia</td>
</tr>
<tr>
<td>Common Anxiety</td>
</tr>
<tr>
<td><strong>Nervous system disorders</strong></td>
</tr>
<tr>
<td>Very common Headache², dizziness, paraesthesia</td>
</tr>
<tr>
<td>Common Taste disorder</td>
</tr>
<tr>
<td><strong>Cardiac disorders</strong></td>
</tr>
<tr>
<td>Very common Tachycardia²</td>
</tr>
<tr>
<td>Category</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td><strong>Common</strong></td>
</tr>
<tr>
<td><strong>Uncommon</strong></td>
</tr>
<tr>
<td><strong>Vascular disorders</strong></td>
</tr>
<tr>
<td>Very common</td>
</tr>
<tr>
<td><strong>Respiratory, thoracic and mediastinal disorders</strong></td>
</tr>
<tr>
<td>Very common</td>
</tr>
<tr>
<td>Common</td>
</tr>
<tr>
<td><strong>Gastrointestinal disorders</strong></td>
</tr>
<tr>
<td>Very common</td>
</tr>
<tr>
<td><strong>Skin and subcutaneous tissue disorders</strong></td>
</tr>
<tr>
<td>Very common</td>
</tr>
<tr>
<td>Common</td>
</tr>
<tr>
<td><strong>Musculoskeletal and connective tissue disorders</strong></td>
</tr>
<tr>
<td>Very common</td>
</tr>
<tr>
<td>Common</td>
</tr>
<tr>
<td><strong>General disorders and administration site conditions</strong></td>
</tr>
<tr>
<td>Very common</td>
</tr>
<tr>
<td><strong>Investigations</strong></td>
</tr>
<tr>
<td>Very common</td>
</tr>
<tr>
<td>Common</td>
</tr>
<tr>
<td>Uncommon</td>
</tr>
</tbody>
</table>

\(^1\) CRS was adjudicated using the ASTCT consensus grading of CRS criteria (Lee et.al 2019).

\(^2\) Adjudicated CRS is provided in lieu of investigator reported CRS.

\(^3\) Some of the events may be associated with CRS or may be isolated reported events.

\(^4\) Includes fatigue and asthenia.

\(^5\) Includes achromotrichia acquired, ephelides, eyelash discoloration, eyelash hypopigmentation, hair colour changes, lentigo, pigmentation disorder, retinal depigmentation, skin depigmentation, skin discoloration, skin hyperpigmentation, skin hypopigmentation, solar lentigo, vitiligo.

\(^6\) Includes eye oedema, eye swelling, eyelid oedema, periorbital swelling, periorbital oedema, swelling of eyelid, pharyngeal oedema, lip oedema, lip swelling, face oedema, generalized oedema, localized oedema, oedema, oedema peripheral, peripheral swelling, swelling, swelling face.

**Description of selected adverse reactions**

**Cytokine release syndrome (CRS)**

In clinical study IMCgp100-202, cytokine release syndrome (adjudicated based on ASTCT consensus grading 2019) occurred in 89% of KIMMTRAK treated patients. The overall incidence of CRS included 12% Grade 1, 76% Grade 2 and 0.8% Grade 3 events. Most commonly observed symptoms with CRS included chills, nausea, vomiting, fatigue, hypotension, and headache. Grade 3 events that may be observed in association with CRS include tachycardia, hypoxia, angina pectoris, atrial flutter, and left ventricular dysfunction.

The majority (84%) of episodes of CRS started the day of infusion. The median time to resolution of CRS was 2 days. CRS rarely (1.2%) led to treatment discontinuation. All CRS symptoms were
reversible and were mostly managed with intravenous fluids, antipyretics, or a single dose of corticosteroid. Two patients (0.8 %) received tocilizumab.

For clinical management of CRS, see section 4.2, Table 1.

Acute skin reactions

In Study IMCgp100-202, acute skin reactions occurred in 91 % of patients treated with KIMMTRAK, including any grade rash (83 %), pruritis (69 %), erythema (25 %) and cutaneous oedema (27 %). Most skin reactions were Grade 1 (28 %) or 2 (44 %) and some KIMMTRAK treated patients experienced Grade 3 (21 %) events. Among patients with observed rash, patients commonly experienced rash (55 %), rash maculo-papular (31 %) and skin exfoliation (21 %). Grade 3 adverse reactions of rash were reported in 5 % of patients and included rash (2.4 %) and rash maculopapular (1.6 %).

Acute skin reactions typically occurred following each of the first three KIMMTRAK infusions, with decreasing frequency of ≥ Grade 3 reactions (dose 1; 17 %, dose 2; 10 %, dose 3; 8 %, dose 4; 3 %). The median time to onset of acute skin reactions was 1 day in the KIMMTRAK treated patients and median time to improvement to ≤ Grade 1 was 6 days.

For clinical management of acute skin reactions, see section 4.2, Table 2.

Elevated liver enzymes

In Study IMCgp100-202 where 95 % of patients had preexisting liver metastasis, ALT/AST increase to ≥ Grade 1 were observed in 65 % of patients treated with KIMMTRAK. Elevations in bilirubin have been reported in 27 % of patients and these were primarily associated with increase in size of liver metastasis. The majority Grade 3 or 4 ALT/AST elevations generally occurred within the first 3 KIMMTRAK infusions. Most patients experiencing Grade 3 or 4 ALT/AST elevations had improvement to ≤ Grade 1 within 7 days.

Immunogenicity

Treatment-emergent anti-drug antibodies (ADA) against tebentafusp were detected in 33 % and 29 % of patients receiving tebentafusp across all doses in study IMCgp100-102 and study IMCgp100-202, respectively. The median onset time to ADA formation was 6 to 9 weeks after start of tebentafusp treatment.

There was no evidence of ADA impact on safety or efficacy of tebentafusp, although the small number of patients who developed high titer ADA precludes firm conclusions regarding their clinical impact.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 Overdose

There is no information on overdose with tebentafusp. In case of overdose, patients should be closely monitored for signs or symptoms of adverse reactions and appropriate symptomatic treatment should be instituted immediately.
5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antineoplastic agents, other antineoplastic agents, ATC code: not yet assigned

Mechanism of action

Tebentafusp is a bispecific fusion protein, comprised of a T cell receptor (TCR; targeting domain) fused to an antibody fragment targeting CD3 (cluster of differentiation 3; effector domain). The TCR end binds with high affinity to a gp100 peptide presented by human leukocyte antigen – A*02:01 (HLA-A*02:01) on the cell surface of uveal melanoma tumour cells, and the effector domain binds to the CD3 receptor on the polyclonal T cell.

An immune synapse is formed when the TCR targeting domain of tebentafusp binds to uveal melanoma cells and the CD3 effector domain binds to polyclonal T cells. This immune synapse results in redirection and activation of polyclonal T cells regardless of their native TCR specificity. Tebentafusp activated polyclonal T cells release inflammatory cytokines and cytolytic proteins, which result in direct lysis of uveal melanoma tumour cells.

Pharmacodynamic effects

Transient and clinically nonsignificant reduction in lymphocyte counts in blood was observed after treatment with tebentafusp. Lymphocytes decreased the day after the first 3 doses and returned to baseline prior to subsequent doses.

After treatment with tebentafusp, transient increases in serum levels of proinflammatory cytokines and chemokines were observed in samples collected after the first three doses. Peak levels were observed between 8 to 24 hours after treatment with tebentafusp and levels returned to baseline prior to subsequent doses.

Clinical efficacy and safety

Study IMCgp100-202: Previously untreated metastatic uveal melanoma

Study IMCgp100-202 was a randomised, open label, multicentre study that enrolled HLA-A*02:01 positive metastatic uveal melanoma patients who were naïve to systemic therapy. Patient could not have received previous systemic treatment or localized (liver--directed) therapy for metastatic uveal melanoma except for a prior surgical resection of oligometastatic disease. Patient were excluded for presence of symptomatic or untreated brain metastasis, symptomatic congestive heart failure, QT interval corrected by Fridericia’s formula (QTcF) > 470 msec or congenital long QT syndrome, acute myocardial infarction, or unstable angina pectoris less than 6 months prior to treatment initiation.

Patients were randomised (2:1) to receive tebentafusp weekly by intravenous infusion according to the recommended intra-patient dosing regimen section 4.2 or investigator’s choice treatment (pembrolizumab, ipilimumab, or dacarbazine) at the approved doses of these agents until disease progression or unacceptable toxicity.

Patients could receive tebentafusp, pembrolizumab, or ipilimumab treatment beyond disease progression if the patients were clinically stable, deriving clinical benefit and showed no signs of unacceptable toxicity as determined by the investigator. Treatment breaks for up to 2 consecutive weeks were allowed. Randomisation was stratified by lactate dehydrogenase (LDH) status, a known prognostic factor for unresectable or metastatic UM.

The primary efficacy outcome was overall survival (OS) in all patients randomised in the study. Tumour assessments were conducted every 12 weeks. Additional efficacy outcomes were investigator
assessed progression free survival (PFS) A total of 378 patients were randomised; 252 to tebentafusp-treated group and 126 to the investigator’s choice treated group (pembrolizumab: 82 %; ipilimumab: 12 %; or dacarbazine: 6 %). The median age was 64 years (range 23 to 92 years); with 49.5 % of patients ≥ 65 years, 87 % were white, 50 % were female. Baseline ECOG performance status was 0 (72 %) or 1 (20.4 %) or 2 (0.3 %), 36 % had elevated LDH level, and 95 % had liver metastasis.

In this study IMCgp100-202, 43 % of patients received treatment beyond progression with tebentafusp with no new safety signals identified. Median duration of tebentafusp treatment beyond progression was 8 weeks. Of the total tebentafusp infusions during the study, 21.5 % was administered after progression.

After completion of the primary efficacy analysis, patients from the investigator’s choice arm were permitted to crossover to the tebentafusp treatment. With a median duration of follow up of 22.4 months, the updated OS continued to favour the tebentafusp arm (HR= 0.58; 95% CI: 0.44, 0.77). At the time of analysis, 16 patients had crossed over to tebentafusp treatment.

The efficacy results are summarized in Table 4 and Figure 1.

Table 4: Efficacy results in study IMCgp100-202

<table>
<thead>
<tr>
<th>Primary and secondary endpoints</th>
<th>KIMMTRAK (N = 252)</th>
<th>Investigator’s choice therapy (N = 126)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Overall survival (OS)</strong>(^1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of deaths</td>
<td>87 (34.5 %)</td>
<td>63 (50 %)</td>
</tr>
<tr>
<td>Median months (95 % CI)</td>
<td>21.7 (18.6, 28.6)</td>
<td>16.0 (9.7, 18.4)</td>
</tr>
<tr>
<td>HR (95 % CI)(^2)(^4)</td>
<td>0.51 (0.37, 0.71)</td>
<td></td>
</tr>
<tr>
<td>Stratified log-rank p-value(^2)</td>
<td>p = &lt;0.0001</td>
<td></td>
</tr>
<tr>
<td><strong>Progression free survival (PFS)</strong>(^3)(^4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number (%) of patients with event</td>
<td>198 (78.6 %)</td>
<td>97 (77 %)</td>
</tr>
<tr>
<td>Median in months (95 % CI)</td>
<td>3.3 (3.0, 5.0)</td>
<td>2.9 (2.8, 3.0)</td>
</tr>
<tr>
<td>HR (95 % CI)(^3)</td>
<td>0.73 (0.58, 0.94)</td>
<td></td>
</tr>
<tr>
<td>Stratified log-rank p-value(^2)</td>
<td>p = 0.0139</td>
<td></td>
</tr>
<tr>
<td><strong>Objective response rate (ORR)</strong>(^6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>n (%)</td>
<td>26 (10.3)</td>
<td>6 (4.8)</td>
</tr>
<tr>
<td>95% CI</td>
<td>6.9, 14.8</td>
<td>1.8, 10.1</td>
</tr>
<tr>
<td>Complete Response (CR)</td>
<td>1 (0.4)</td>
<td>0</td>
</tr>
<tr>
<td>Partial Response (PR)</td>
<td>25 (9.9)</td>
<td>6 (4.8)</td>
</tr>
<tr>
<td>Stable Disease (SD)(^5)</td>
<td>52 (20.6)</td>
<td>16 (12.7)</td>
</tr>
<tr>
<td><strong>Median duration of response</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Months (95% CI)</td>
<td>9.9 (5.6, 22.1)</td>
<td>9.7 (2.7, --)</td>
</tr>
</tbody>
</table>

CI = Confidence interval, HR = Hazard ratio

\(^1\) At a prespecified interim analysis, 150 OS events were observed, and a p-value boundary for declaring efficacy (0.006) was determined by a Lan-Demets alpha spending function with O’Brien Fleming type boundary.

\(^2\) Two-sided p-value based on log rank test stratified by LDH.

\(^3\) As assessed by investigator using RECIST v1.1 criteria.

\(^4\) Hazard ratio is from a proportional hazards model stratified by LDH status.

\(^5\) Based on ≥24 weeks.

\(^6\) Updated based on all patients having opportunity for at least 3 radiological assessments.
Study IMCgp100-102: Previously treated metastatic uveal melanoma

Study IMCgp100-102 was an open-label, Phase 2 multicentre study conducted in 127 patients, who were treated with the dosing scheme recommended in section 4.2. Patients were required to be HLA-A*02:01 positive. Patients were eligible if they had experienced disease progression following at least 1 or more prior lines of liver directed therapy or systemic therapy including immune check point inhibitors in the metastatic setting. Patients were excluded for clinically significant cardiac disease and presence of symptomatic or untreated brain metastasis.

Major efficacy outcome measures included confirmed ORR as assessed by Independent Central Review (ICR) using Response Evaluation Criteria in Solid Tumours (RECIST) v1.1. Secondary efficacy outcomes included PFS, DCR, DOR and OS.

The median age was 61 years, 50 % were female, 99 % were white, the ECOG performance score was 0 (70 %) or 1 (30 %) and 96 % of patients had liver metastasis. Prior treatments included immunotherapy (73 % of patients) including immune checkpoint inhibitors (PD-1/PD-L1; 65 %; CTLA-4; 31 %) and liver directed therapy 45%. Efficacy results from study IMCgp100-102 are summarised in Table 5.

Table 5: Efficacy results in study IMCgp100-102

<table>
<thead>
<tr>
<th>Primary and secondary endpoints</th>
<th>KIMMTRAK (N = 127)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confirmed objective response rate¹</td>
<td>6 (4.7 %)</td>
</tr>
<tr>
<td>(95% CI)</td>
<td>(1.8 %, 10 %)</td>
</tr>
<tr>
<td>Complete response (CR)</td>
<td>0</td>
</tr>
<tr>
<td>Partial Response (PR)</td>
<td>6 (4.7 %)</td>
</tr>
<tr>
<td>Stable Disease (SD)</td>
<td>23 (18.1 %)</td>
</tr>
<tr>
<td>Median duration of response</td>
<td>Months (95% CI)</td>
</tr>
<tr>
<td></td>
<td>8.7 (5.6, 24.5)</td>
</tr>
</tbody>
</table>

¹ As assessed by independent central review using RECIST v1.1 criteria.
² Based on ≥24 weeks

Paediatric population
The European Medicines Agency has waived the obligation to submit the results of studies with KIMMTRAK in all subsets of the paediatric population in the treatment of ocular melanoma (see section 4.2 for information on paediatric use).

5.2 Pharmacokinetic properties

Absorption

The pharmacokinetics of tebentafusp appear linear and dose proportional over a dose range of 20 mcg to 68 mcg. Following weekly intravenous infusion in metastatic uveal melanoma patients, the maximum plasma concentrations (C_max) reached 4.2 ng/mL - 13.7 ng/mL immediately at the end of infusion (T = 0.5 hours). No accumulation was observed with a weekly dosing regimen at the target therapeutic doses.

Distribution

Tebentafusp did not distribute extensively and displayed a volume of distribution comparable to blood volume (5.25 L).

Biotransformation

The metabolic pathway of tebentafusp has not been characterised. Like other protein therapeutics, tebentafusp is expected to be degraded into small peptides and amino acids via catabolic pathways.

Elimination

The excretion of tebentafusp is not fully characterised. Based on its molecular size that is close to the glomerular filtration size exclusion threshold, small amounts of tebentafusp may be excreted in the urine.

Following administration of tebentafusp in metastatic uveal melanoma patients the estimated systemic clearance was 4.29 L/d, with a terminal half-life of 6 to 8 hours.

Special populations

Population pharmacokinetic analysis indicated that there was no significant effect of weight (43 to 163 kg), gender, race, and age (23 to 91 years) on tebentafusp clearance.

Renal impairment

No formal pharmacokinetic studies of tebentafusp have been conducted in patients with renal impairment.

No impact on safety or efficacy parameters was identified in patients with mild (creatinine clearance [CrCL] ranging 60 to 89 mL/min) to moderate (CrCL ranging 30 to 59 mL/min) renal impairment and no dose adjustments are recommended. There are limited data from patients (< 5%) with moderate renal impairment and there is no information available from patients with severe renal impairment (CrCL < 30 mL/min).

Hepatic impairment

No formal pharmacokinetic studies of tebentafusp have been conducted in patients with hepatic impairment. Population PK analyses demonstrated that baseline and on treatment ALT/AST elevations did not impact tebentafusp pharmacokinetics. No dose adjustments based on ALT/AST levels are recommended.
5.3 Preclinical safety data

Tebentafusp is a human–specific protein and there are no relevant animal species in which nonclinical toxicology of tebentafusp could be tested.

No carcinogenicity, genotoxicity, or developmental and reproductive toxicity studies have been conducted with tebentafusp.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Citric acid monohydrate (E330)
Di-sodium hydrogen phosphate (E339)
Mannitol (E421)
Trehalose
Polysorbate 20 (E432)
Water for injections

6.2 Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

6.3 Shelf life

Unopened vial

3 years.

After opening

From a microbiological point of view, once opened, the medicinal product should be diluted and infused immediately.

After preparation of solution for infusion

Chemical and physical in-use stability has been demonstrated for 24 hours at 2 °C to 8 °C.

From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user.

6.4 Special precautions for storage

Store and transport refrigerated (2 °C – 8 °C).
Keep the vial in the outer carton in order to protect from light.
For storage conditions after dilution of the medicinal product, see section 6.3.

6.5 Nature and contents of container

Type I glass vial with a bromobutyl rubber stopper and an aluminium/plastic flip-off seal, containing 0.5 mL concentrate.

Pack size of 1 vial.

6.6 Special precautions for disposal and other handling
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

General precautions

The solution for infusion should be prepared by a healthcare professional using proper aseptic technique throughout the handling of this medicinal product.

Use aseptic technique for dilution and preparation of dosing solutions.

Closed system transfer devices (CSTDs) must not be used for dose preparation of KIMMTRAK solution for infusion.

Parenteral medicinal products and infusion bags should be inspected visually for particulate matter and discolouration prior to administration, whenever solution and container permit.

Preparation

KIMMTRAK must be diluted prior to intravenous administration.

Ensure the following supplies are available prior to preparing KIMMTRAK for administration:
- 1 mL sterile syringes with graduations of 2 decimal places.
- Sterile needles.
- Human albumin; use concentration as per local availability. Local concentrations include but not restricted to 4 % (40 g/L), 5 % (50 g/L), 20 % (200 g/L), 25 % (250 g/L).
- A 100 mL infusion bag containing sodium chloride 9 mg/mL (0.9 %) solution for injection:
  - The infusion bag should be constructed of polyolefins (PO) [such as polyethylene (PE) and polypropylene (PP)] or polyvinyl chloride (PVC).
- A sterile, nonpyrogenic, low protein binding 0.2 micron in-line filter infusion set for administration of the final infusion bag.

Dilution and Administration

A 2-step process is required for preparation of the final KIMMTRAK dose:

Step 1: Prepare the infusion bag

Using aseptic technique, prepare the infusion bag as follows:

a. Using a 1 mL syringe and a sterile needle, withdraw the calculated volume of human albumin into the syringe (see Table 6 below) and add to the 100 mL infusion bag containing sodium chloride 9 mg/mL (0.9 %) solution for injection to make a final human albumin concentration between 225 mcg/mL and 275 mcg/mL.

<table>
<thead>
<tr>
<th>Human albumin concentration</th>
<th>Acceptable volume range for addition to 100 mL infusion bag for human albumin concentration between 225 mcg/mL to 275 mcg/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 % (40 g/L)</td>
<td>0.63 mL (0.57 mL to 0.69 mL)</td>
</tr>
<tr>
<td>5 % (50 g/L)</td>
<td>0.50 mL (0.45 mL to 0.55 mL)</td>
</tr>
<tr>
<td>20 % (200 g/L)</td>
<td>0.13 mL (0.12 mL to 0.14 mL)</td>
</tr>
<tr>
<td>25 % (250 g/L)</td>
<td>0.10 mL (0.09 mL to 0.11 mL)</td>
</tr>
</tbody>
</table>

b. Gently homogenize the diluted solution by completing the following steps:
  i. Invert the infusion bag so that the entry port is positioned at the top of the bag and tap the side of port tubing to ensure that any residual solution is released into the bulk solution.
ii. Mix by gently rotating the bag lengthwise 360 degrees from the inverted position at least 5 times. Do NOT shake the infusion bag.

iii. Repeat (i) and (ii) an additional three times.

Step 2: Preparation of KIMMTRAK solution for infusion

c. Using a 1 mL syringe and a sterile needle, withdraw the required volume of KIMMTRAK 100 micrograms / 0.5 mL as per the dose required (shown in Table 6 below) and add to the prepared 100 mL infusion bag containing sodium chloride 9 mg/mL (0.9 %) solution for injection, plus human albumin.

Table 7: KIMMTRAK volumes required for addition to infusion bag

<table>
<thead>
<tr>
<th>Day of treatment</th>
<th>Dose (mcg) of KIMMTRAK</th>
<th>Volume (mL) of KIMMTRAK</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day 1</td>
<td>20</td>
<td>0.10</td>
</tr>
<tr>
<td>Day 8</td>
<td>30</td>
<td>0.15</td>
</tr>
<tr>
<td>Day 15 and weekly thereafter</td>
<td>68</td>
<td>0.34</td>
</tr>
</tbody>
</table>

d. Do NOT flush the needle and syringe on transfer. Discard the vial containing the unused portion of KIMMTRAK in accordance with local requirements. Do not prepare more than one dose from the vial.

e. Mix the infusion bag by following the same procedure outlined in Step 1b.

Administration

- Administer KIMMTRAK as intravenous infusion only.
- Immediately administer the infusion over 15 to 20 minutes through a dedicated intravenous line. A sterile, nonpyrogenic, low protein binding 0.2 micron in line filter infusion set should be used. Administer the entire contents of the KIMMTRAK infusion bag to the patient.
- Upon completion of KIMMTRAK infusion, flush the infusion line with adequate volume of sterile sodium chloride 9 mg/mL (0.9 %) solution for injection, to ensure that the entire contents of the infusion bag are administered. Do not administer KIMMTRAK as an intravenous push or bolus. Do not mix KIMMTRAK with other drugs or administer other drugs through the same intravenous line.

Storage of prepared infusion bag

- KIMMTRAK does not contain a preservative. The prepared infusion bag should be administered within 4 hours from the time of preparation including the duration of infusion. During the 4 hour window, the KIMMTRAK infusion bag should remain below 30 °C.
- If not used immediately, store the KIMMTRAK infusion bag in a refrigerator at 2 °C to 8 °C for up to 24 hours from the time of preparation which includes the time allowed for equilibration of the infusion bag to room temperature and the duration of the infusion.
- Once removed from the refrigerator, KIMMTRAK infusion bag must not be refrigerated again. Discard unused KIMMTRAK solution beyond the recommended storage time.

7. MARKETING AUTHORISATION HOLDER

Immunocore Ireland Limited
Unit 1, Sky Business Centre
Dublin 17, D17 FY82
Ireland
8. MARKETING AUTHORISATION NUMBER(S)

EU/1/22/1630/001

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu
ANNEX II

A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORIZATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer of the biological active substance

AGC Biologics A/S
Vandtaarnsvej 83B,
DK-2860 Soeborg, Copenhagen
Denmark

Name and address of the manufacturer responsible for batch release

ProPharma Group The Netherlands B.V.,
Schipholweg 73
2316 ZL Leiden
The Netherlands

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORIZATION

• Periodic safety update reports (PSURs)

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c (7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder (MAH) shall submit the first PSUR for this product within 6 months following authorisation.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

• Risk management plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

• At the request of the European Medicines Agency;
• Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

• Additional risk minimisation measures

Prior to the launch of KIMMTRAK in each Member State the Marketing Authorisation Holder (MAH) must agree about the content and format of the educational programme, including communication
media, distribution modalities, and any other aspects of the programme, with the National Competent Authority.

The educational programme is aimed at highlighting the monitoring process and facilitating the prompt diagnosis and treatment of cytokine release syndrome (CRS) to reduce its severity.

The MAH shall ensure that in each Member State where KIMMTRAK is marketed, all healthcare professionals and patients who are expected to prescribe or use KIMMTRAK have access to/are provided with the following educational materials:

- Physician educational material
- Patient information pack

**Physician educational material:**
- The Summary of Product Characteristics
- Treatment Guide for Healthcare Professionals

**Treatment Guide for Healthcare Professionals:**
- Details on how to monitor patients for the first three infusions and for subsequent infusions.
- Details of how to minimise the risk of hypotension associated with CRS.
- Description of the symptoms of CRS, including severity, frequency, time to onset, treatment, and resolution, in patients treated with KIMMTRAK.
- Details on how to manage CRS based on severity grade, including the recommendation to administer corticosteroid premedication for Grade 2 CRS that is persistent or recurrent or any Grade 3 CRS.
- Description of the ECG schedule and management requirements based on the ECG results.
- Recommendation to carefully monitor patients with cardiac disease, QT prolongation and risk factors for cardiac failure.
- Information on the importance of informing patients of the risk of CRS and the need to immediately contact their doctor or nurse if they develop symptoms of CRS.
- Information on the importance of reporting adverse reactions with details of how to report.

**The patient information pack:**
- Package leaflet
- Patient Guide

**Patient Guide:**
- Information on the risk of CRS associated with KIMMTRAK with a description of the symptoms.
- Information on the importance of immediately contacting a doctor or nurse if the patient develops symptoms of CRS.
- Details of what the patient should expect regarding the monitoring schedule.
- Information on the importance of reporting side effects with details of how to report.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON

1. NAME OF THE MEDICINAL PRODUCT

KIMMTRAK 100 micrograms/0.5 mL concentrate for solution for infusion
tebentafusp

2. STATEMENT OF ACTIVE SUBSTANCE(S)

One vial of 0.5 mL contains 100 micrograms of tebentafusp

3. LIST OF EXCIPIENTS

Citric acid monohydrate (E 330), Di-sodium hydrogen phosphate (E 339), Mannitol (E 421),
Trehalose, Polysorbate 20 (E 432), and Water for injections. See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Concentrate for solution for infusion
1 vial

5. METHOD AND ROUTE(S) OF ADMINISTRATION

For intravenous use after dilution.
Read the package leaflet before use.
For single use only.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT
OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store and transport refrigerated (2 °C – 8 °C).
Keep the vial in the outer carton in order to protect from light.
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Immunocore Ireland Limited
Unit 1, Sky Business Centre
Dublin 17, D17 FY82
Ireland

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/22/1630/001

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Justification for not including Braille accepted.

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN
**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**VIAL LABEL**

1. **NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION**

   KIMMTRAK 100 mcg/0.5 mL sterile concentrate
tebentafusp
IV after dilution

2. **METHOD OF ADMINISTRATION**

   Read the package leaflet before use.

3. **EXPIRY DATE**

   EXP

4. **BATCH NUMBER**

   Lot

5. **CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT**
B. PACKAGE LEAFLET
Package leaflet: Information for the patient

KIMMTRAK 100 micrograms/0.5 mL concentrate for solution for infusion
tebentafusp

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you are given this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or nurse.
- If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What KIMMTRAK is and what it is used for
2. What you need to know before you are given KIMMTRAK
3. How KIMMTRAK is given
4. Possible side effects
5. How to store KIMMTRAK
6. Contents of the pack and other information

1. What KIMMTRAK is and what it is used for

KIMMTRAK contains the active substance tebentafusp. Tebentafusp is an anticancer medicine made from two different proteins that are fused together. One of these proteins recognises and attaches to an antigen (a target protein) called ‘gp100’. Gp100 is found at high levels in uveal melanoma cancer cells. The other protein recognises and attaches to a protein called CD3. CD3 is found on certain cells of the body’s immune system. By binding to gp100 and CD3, KIMMTRAK activates your immune system to recognise and destroy the cancer cells.

KIMMTRAK is used to treat adults with a rare eye cancer called ‘uveal melanoma’. The medicine is used when the uveal melanoma has grown despite local treatment, or has spread to other parts of the body.

2. What you need to know before you are given KIMMTRAK

Do not use KIMMTRAK if you are allergic to tebentafusp or any of the other ingredients of this medicine (listed in section 6). If you are not sure whether you are allergic to any of the ingredients, talk to your doctor or nurse before you are given KIMMTRAK.

Warnings and precautions

Talk to your doctor or nurse before you are given KIMMTRAK, about all of your medical conditions, particularly if you have following:
- heart problems including a change in the electrical activity of your heart (QT interval prolongation)

Your doctor may give you a blood test called HLA genotyping before treatment to determine if KIMMTRAK is suitable for you.

Tell your doctor before being given KIMMTRAK if you are taking corticosteroid medication to treat adrenal insufficiency (also known as ‘Addison’s disease’). Your doctor may need to adjust your corticosteroid dose while you are being treated with KIMMTRAK.
Tell your doctor or nurse immediately or seek urgent medical attention if you have any of the following side effects during or after your treatment:

- fever, dizziness, light headedness. These may be symptoms of a serious condition called cytokine release syndrome. Other symptoms of cytokine release syndrome are difficulty breathing, nausea, vomiting, fatigue, muscle pain, joint pain, swelling, low blood pressure, rapid heart rate, or headache.
- itchy skin, rash, severe hives (itchy swellings under the skin), peeling or flaking skin, or swelling of body and/or skin around the eyes which may be symptoms of skin reactions.
- heart problems such as rapid or irregular heart beat or a change in the electrical activity of the heart that can cause serious irregular heart rhythms which can manifest as palpitations, shortness of breath, light headedness or dizziness, or chest pain.

Your doctor or nurse will monitor you for signs and symptoms of these reactions during and after each dose. If you have any severe problems, your treatment may be temporarily stopped and started again when you feel better.

**Children and adolescents**
Do not give this medicine to children under the age of 18 years. This is because there is limited information on how well it works in this age group.

**Other medicines and KIMMTRAK**
Tell your doctor if you are taking, have recently taken or might take any other medicines.

**Pregnancy, breast-feeding and fertility**
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.

**Pregnancy**
KIMMTRAK should not be used in pregnancy unless you and your doctor agree the benefit of taking this medicine outweighs any potential risks. If you are a woman who can become pregnant, your doctor or nurse will give you a pregnancy test before you start treatment with KIMMTRAK. If you become pregnant during KIMMTRAK treatment, inform your doctor or nurse immediately.

**Contraception**
If you are female and of child bearing age, you must use effective birth control (contraception) to avoid becoming pregnant during KIMMTRAK treatment and for at least 1 week after your last dose. Discuss with your doctor the most appropriate methods of birth control.

**Breast-feeding**
You should not breast-feed during treatment with KIMMTRAK. It is not known if KIMMTRAK passes into your breast milk.

**Driving and using machines**
KIMMTRAK is unlikely to affect your ability to drive or use machines. If you feel unwell while being treated with this medicine you should not drive or operate machinery until you feel well again.

**KIMMTRAK contains sodium**
This medicine contains less than 1 mmol sodium (23 mg) per mL, that is to say essentially ‘sodium-free’.

3. **How KIMMTRAK is given**
This medicine will be given to you by a doctor or nurse in a hospital or an outpatient setting.
You may be given fluids by infusion (drip) before each KIMMTRAK infusion to help prevent low blood pressure due to cytokine release syndrome (see section 2 and 4).

Your doctor or nurse will give you KIMMTRAK through an infusion (drip) into your vein (intravenous) over 15 to 20 minutes. You will be given KIMMTRAK once a week, for as long your doctor thinks you are benefitting from the treatment.

The recommended dose of KIMMTRAK is:
- Day 1: 20 micrograms
- Day 8: 30 micrograms
- Day 15: 68 micrograms

Once every week thereafter: 68 micrograms

The first three doses will be given to you in hospital. You will be monitored for any side effects during treatment and for at least 16 hours after each dose.

If the first three doses do not cause any serious or unmanageable side effects, your next doses may be given in an outpatient setting. You will be monitored for any side effects during treatment and for at least 60 minutes after each dose. If you have received KIMMTRAK treatment in an outpatient setting for at least 3 months without a break lasting longer than 2 weeks, then monitoring may be decreased after each dose to at least 30 minutes.

If you miss an appointment for your next KIMMTRAK dose, contact your doctor or nurse as soon as possible to reschedule your appointment.

If you have any further questions on the use of this medicine, ask your doctor or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Tell your doctor or nurse immediately or seek urgent medical attention if you experience any of the following very common side effects during or after treatment:
- Fever, dizziness, light headedness. These may be symptoms of a serious condition called ‘cytokine release syndrome’. Other symptoms of cytokine release syndrome are difficulty breathing, nausea, vomiting, fatigue, muscle pain, joint pain, swelling, low blood pressure, rapid heart rate, or headache. These symptoms mostly occur after the first three infusions.
- Itchy skin, rash, severe hives(itchy swellings under the skin, peeling or flaking skin, swelling of the body and/or skin around the eyes, which may be symptoms of skin reactions. These symptoms mostly occur after the first three infusions.
- Heart problems such as rapid or irregular heart beat or a change in the electric activity of the heart that can cause serious irregular heart rhythms which can manifest as palpitations, shortness of breath, light headedness or dizziness, or chest pain.

Other side effects
Tell your doctor if you notice any of the following side effects:

Very common side effects (may affect more than 1 in 10 people)
- Decreased appetite
- Prickling, tingling or numbness in any part of the body
- Cough
- Diarrhoea
- Constipation
- Indigestion
- Stomach pain
• Chills
• Trouble sleeping (insomnia)
• Flu like symptoms
• Inability to sleep
• Flushing of the skin
• High blood pressure
• Dry skin
• Changes in skin colour
• Redness of skin
• Decreased level of phosphate in the blood
• Decreased level of magnesium in the blood
• Decreased level of sodium in the blood
• Decreased level of calcium in the blood
• Decreased level of potassium in the blood
• Decreased haemoglobin in the blood
• Increased levels of liver enzymes in the blood, which may be a sign of liver problems
• Increased levels of bilirubin in the blood, which may be a sign of liver problems
• Increased level of the pancreatic enzyme lipase in the blood, which may be a sign of pancreas problems
• Decreased level of white blood cells in the blood
• Pain in back, arms or legs

Common side effects (may affect up to 1 in 10 people)
• Infection of the nose and throat
• Pain in the mouth and throat
• Hair loss
• Excessive sweating during the night
• Anxiety
• Changes in ability to taste
• Changed or irregular heart beat
• Shortness of breath
• Muscle spasms
• Increased level of the pancreatic enzyme, amylase in the blood
• Increased level of creatinine in the blood, which may be sign of the kidney problems
• Increased level of the liver enzyme gamma glutamyltransferase in the blood
• Increased level of white blood cells in the blood
• Increased level of liver enzymes in the blood
• Increased level of alkaline phosphatase in the blood
• Increased level of blood glucose in the blood

Uncommon side effects (may effect up to 1 in 100 people)
• Increased levels of potassium, phosphate, and uric acid in the blood, which are signs of cancer cells dying
• Chest discomfort or pain, which may be a sign of heart problems
• Heart failure (shortness of breath, chest discomfort, swelling of legs and ankles)
• Changes in the electrical activity of the heart that can lead to serious irregular heart rhythms.

Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
5. How to store KIMMTRAK

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the vial label and carton after EXP. The expiry date refers to the last day of that month.

Unopened vials should be stored at 2 °C to 8 °C.

Keep the vial in the outer carton to protect from light.

If not used immediately, the prepared infusion may be stored below 30 °C for up to 4 hours or at 2 °C to 8 °C for 24 hours from the time of preparation/dilution until the end of administration.

Do not use this medicine if you notice visible signs of deterioration (i.e. particles, discolouration).

Do not store any unused medicine for reuse. Any unused medicine or waste material should be disposed of in accordance with local requirements. These measures will help protect the environment.

6. Contents of the pack and other information

What KIMMTRAK contains
- The active substance is tebentafusp. One vial of 0.5 mL concentrate contains 100 micrograms of tebentafusp.
- The other ingredients are citric acid monohydrate (E330), di-sodium hydrogen phosphate (E339), mannitol (E421), trehalose, polysorbate 20 (E432), and water for injections (see section 2).

What KIMMTRAK looks like and contents of the pack
KIMMTRAK concentrate for solution for infusion (sterile concentrate) is a clear, colourless to slightly yellowish solution in a single-dose vial.

The pack size is 1 glass vial per carton.

Marketing Authorisation Holder
Immunocore Ireland Limited
Unit 1, Sky Business Centre
Dublin 17, D17 FY82
Ireland

Manufacturer
Baxter Oncology GmbH
Kantstraße 2
33790 Halle/Westfalen
Germany

This leaflet was last revised in

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.

This leaflet is available in all EU/EEA languages on the European Medicines Agency website.
The following information is intended for healthcare professionals only:

**Important:** Please refer to the Summary of Product Characteristics (SmPC) before using.

**General precautions**

The solution for infusion should be prepared by a healthcare professional using proper aseptic technique throughout the handling of this medicinal product.

Closed system transfer devices (CSTDs) **must not be used** for dose preparation of KIMMTRAK solution for infusion.

Parenteral drug products and infusion bags should be inspected visually for particulate matter and discolouration prior to administration, whenever solution and container permit.

**Preparation**

KIMMTRAK must be diluted prior to intravenous administration. Each vial of KIMMTRAK is intended for single-use only. **Do NOT shake the KIMMTRAK vial.**

Ensure the following supplies are available prior to preparing KIMMTRAK for administration:

- 1 mL sterile syringes with graduations of 2 decimal places.
- Sterile needles.
- Human albumin; use concentration as per local availability. Local concentrations include but not restricted to 4 % (40 g/L), 5 % (50 g/L), 20 % (200 g/L), 25 % (250 g/L).
- A 100 mL infusion bag containing sodium chloride 9 mg/mL (0.9 %) solution for injection.
  - The infusion bag should be constructed of polyolefins (PO) [such as polyethylene (PE) and polypropylene (PP)] or polyvinyl chloride (PVC).
- A sterile, non-pyrogenic, low protein binding 0.2 micron in-line filter infusion set for administration of the final infusion bag.

**Dilution and Administration**

A 2-step process is required for preparation of the final KIMMTRAK dose:

**Step 1: Prepare the infusion bag**

Using aseptic technique, prepare the infusion bag as follows:

a. Using a 1 mL syringe and a sterile needle, withdraw the calculated volume of human albumin into the syringe (see Table 1 below) and add to the 100 mL infusion bag containing sodium chloride 9 mg/mL (0.9 %) solution for injection to make a final human albumin concentration between 225 mcg/mL and 275 mcg/mL.

<table>
<thead>
<tr>
<th>Human albumin concentration</th>
<th>Acceptable volume range for addition to 100 mL infusion bag for human albumin concentration between 225 mcg/mL to 275 mcg/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 % (40 g/L)</td>
<td>0.63 mL (0.57 mL to 0.69 mL)</td>
</tr>
<tr>
<td>5 % (50 g/L)</td>
<td>0.50 mL (0.45 mL to 0.55 mL)</td>
</tr>
<tr>
<td>20 % (200 g/L)</td>
<td>0.13 mL (0.12 mL to 0.14 mL)</td>
</tr>
<tr>
<td>25 % (250 g/L)</td>
<td>0.10 mL (0.09 mL to 0.11 mL)</td>
</tr>
</tbody>
</table>

b. Gently homogenize the diluted solution by completing the following steps:
i. Invert the infusion bag so that the entry port is positioned at the top of the bag and tap the side of port tubing to ensure that any residual solution is released into the bulk solution.

ii. Mix by gently rotating the bag lengthwise 360 degrees from the inverted position at least 5 times. Do NOT shake the infusion bag.

iii. Repeat (i) and (ii) an additional three times.

Step 2: Preparation of KIMMTRAK solution for infusion

c. Using a 1 mL syringe and a sterile needle, withdraw the required volume of KIMMTRAK 100 micrograms/0.5 mL as per the dose required (shown in Table 2 below) and add to the prepared 100 mL infusion bag containing sodium chloride 9 mg/mL (0.9 %) solution for injection, plus human albumin.

d. Do NOT flush the needle and syringe on transfer. Discard the vial containing the unused portion of KIMMTRAK in accordance with local requirements. Do not prepare more than one dose from the vial.

Table 2: KIMMTRAK volumes required for addition to infusion Bag

<table>
<thead>
<tr>
<th>Day of treatment</th>
<th>Dose (mcg) of KIMMTRAK</th>
<th>Volume (mL) of KIMMTRAK</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day 1</td>
<td>20</td>
<td>0.10</td>
</tr>
<tr>
<td>Day 8</td>
<td>30</td>
<td>0.15</td>
</tr>
<tr>
<td>Day 15 and weekly thereafter</td>
<td>68</td>
<td>0.34</td>
</tr>
</tbody>
</table>

e. Mix the infusion bag by following the same procedure outlined in Step 1b.

Administration

- Administer KIMMTRAK as intravenous infusion only.
- Immediately administer the infusion over 15 to 20 minutes through a dedicated intravenous line. A sterile, nonpyrogenic, low protein binding 0.2 micron in line filter infusion set should be used. Administer the entire contents of the KIMMTRAK infusion bag to the patient.
- Upon completion of KIMMTRAK infusion, flush the infusion line with adequate volume of sterile sodium chloride 9 mg/mL (0.9 %) solution for injection, to ensure that the entire contents of the infusion bag are administered. Do not administer KIMMTRAK as an intravenous push or bolus. Do not mix KIMMTRAK with other drugs or administer other drugs through the same intravenous line.

Storage of prepared infusion bag

- KIMMTRAK does not contain a preservative. The prepared infusion bag should be administered within 4 hours from the time of preparation including the duration of infusion. During the 4 hour window, the KIMMTRAK infusion bag should remain below 30 °C.
- If not used immediately, store the KIMMTRAK infusion bag in a refrigerator at 2 °C to 8 °C for up to 24 hours from the time of preparation which includes the time allowed for equilibration of the infusion bag to room temperature and the duration of the infusion.
- Once removed from the refrigerator, KIMMTRAK infusion bag must not be refrigerated again. Discard unused KIMMTRAK solution beyond the recommended storage time.